Today: 10 July 2026
AAOI stock dips in premarket as Applied Optoelectronics heads into earnings week
23 February 2026
1 min read

AAOI stock dips in premarket as Applied Optoelectronics heads into earnings week

New York, Feb 23, 2026, 08:38 (EST) — Premarket

  • AAOI dropped about 1.7% in premarket trading, paring gains from Friday’s 10% jump.
  • Applied Optoelectronics is set to report quarterly earnings on Thursday.
  • Forecasts tied to data center and broadband network spending are drawing traders’ attention.

Shares of Applied Optoelectronics fell about 1.7% to $50.79 before the open on Monday, retracing some ground after a 10% jump in the previous session. The company’s quarterly report lands later this week, drawing investor attention.

AAOI’s no stranger to volatility. Shares have whipsawed in recent sessions and are currently parked just under their 12-month high—not much wiggle room if earnings come up short.

The real test lands Thursday, when fourth-quarter results hit. This stock has been moving on anticipation, so even hints about 2026 demand or margins could steer sentiment for the week.

MarketBeat analysts project a loss of 12 cents a share for the quarter. Revenue? Expectations are hovering around $131.6 million.

Rosenblatt Securities maintained its “buy” rating and left the $50 price target unchanged, according to a note flagged by American Banking News over the weekend. americanbankingnews.com

Applied Optoelectronics is stepping up its investor pitch ahead of earnings, organizing a session for investors during the Optical Fiber Communication Conference (OFC) on March 17. CFO Stefan Murry will take the lead at the event, which comes as the company pushes its optical and fiber-coax networking gear for AI data centers and broadband.

Tech earnings are piling up this week, and no surprise, Nvidia is right in the spotlight. Susquehanna analyst Christopher Rolland is betting on “better results and guidance” as momentum for the next platform builds. Rolland figures AI demand should benefit if hyperscale capital spending ramps up. Kiplinger

Bulls in AAOI want to see strong results and nothing unexpected in guidance. The risk? Simple enough: any hint of weaker orders, higher expenses, or a more cautious tone from management—and this stock, already on a tear, could stumble.

Focus shifts to Thursday, when results hit after the bell and the management call could set the tone. Investors are also eyeing the OFC investor session slated for March 17 for more on the demand outlook.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • ATI (ATI) beats S&P 500 with 1.73% gain; outlook for earnings strong
    July 9, 2026, 8:32 PM EDT. ATI finished up 1.73% at $109.76, beating the S&P 500, which rose 0.79%. Over the past month, ATI shares are up almost 10%, ahead of the Aerospace sector's 0.55% move. Analysts see the company posting $0.89 in EPS for the upcoming report, up 12.66% from last year, on $1.19 billion revenue. Full year, ATI is forecast for $3.2 in EPS and $4.6 billion in revenue, showing increases of 30% and 5.5%. ATI is still rated Zacks Rank #2 (Buy), trading at a forward P/E of 33.74, a bit below the industry average. PEG comes in at 1.37, pointing to what some see as fair value on growth expectations. The Aerospace - Defense Equipment group is in the top 41% of industries by Zacks, providing some sector support.
NatWest share price ticks up as buyback filing lands — here’s what investors watch next
Previous Story

NatWest share price ticks up as buyback filing lands — here’s what investors watch next

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus
Next Story

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Go toTop